Silvia Affò, Ramón Bataller  Journal of Hepatology 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Don C. Rockey  Clinical Gastroenterology and Hepatology 
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Volume 65, Issue 1, Pages S82-S94 (October 2016)
Inflammasomes in liver diseases
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Novel insights in the interplay between inflammation and metabolic diseases: A role for the pathogen sensing kinase PKR  Nicolas Marsollier, Pascal Ferré,
The yin and yang of evasion and immune activation in HCC
The inflammasome in liver disease
Anatoliy I. Masyuk, Tatyana V. Masyuk, Nicholas F. LaRusso 
Obesity, inflammation, and liver cancer
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Hepcidin in human iron disorders: Therapeutic implications
Volume 47, Issue 1, Pages (July 2007)
Don C. Rockey  Clinical Gastroenterology and Hepatology 
NS5A inhibitors in the treatment of hepatitis C
Hedgehog signaling in the liver
Agustín Albillos, Margaret Lario, Melchor Álvarez-Mon 
Volume 65, Issue 1, Pages S82-S94 (October 2016)
Immigration and viral hepatitis
Roles for Chemokines in Liver Disease
Volume 66, Issue 1, Pages 1-4 (January 2017)
Nicolas Moniaux, Jamila Faivre  Journal of Hepatology 
Gut–liver immunity Journal of Hepatology
Volume 59, Issue 3, Pages (September 2013)
The progenitor cell dilemma: Cellular and functional heterogeneity in assistance or escalation of liver injury  Veronika Lukacs-Kornek, Frank Lammert 
Marina Berenguer, Detlef Schuppan  Journal of Hepatology 
Inflammation and portal hypertension – The undiscovered country
From immunosuppression to tolerance
Hepatitis C core protein – The “core” of immune deception?
Signalling pathways in alcohol-induced liver inflammation
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
I. Carmona, P. Cordero, J. Ampuero, A. Rojas, M. Romero-Gómez 
Targeting gut flora to prevent progression of hepatocellular carcinoma
Mechanisms of iron hepatotoxicity
Ariane Mallat, Sophie Lotersztajn  Journal of Hepatology 
The yin and yang of evasion and immune activation in HCC
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 45, Issue 4, Pages (October 2006)
Autophagy and senescence in fibrosing cholangiopathies
Autophagy in the liver Journal of Hepatology
Volume 59, Issue 3, Pages (September 2013)
Hepatic fibrosis: Concept to treatment
Veronika Lukacs-Kornek, Detlef Schuppan  Journal of Hepatology 
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
Volume 66, Issue 1, Pages (January 2017)
Cannabinoid signaling and liver therapeutics
Karel J. van Erpecum, Frank G. Schaap  Journal of Hepatology 
Herbert Tilg, Gökhan S. Hotamisligil  Gastroenterology 
Death receptor-mediated apoptosis and the liver
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
NASH animal models: Are we there yet?
Volume 61, Issue 1, Pages S79-S90 (November 2014)
Salvatore Papa, Concetta Bubici  Journal of Hepatology 
Immigration and viral hepatitis
Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma
Volume 63, Issue 1, Pages (July 2015)
Macrophage heterogeneity in liver injury and fibrosis
The dynamic biliary epithelia: Molecules, pathways, and disease
Autophagy in liver diseases: Time for translation?
Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives  Pierre Ronco, Christos Chatziantoniou 
Tatiana Kisseleva, David A. Brenner  Journal of Hepatology 
Statins: Old drugs as new therapy for liver diseases?
Pathogenesis of cholestatic hepatitis C
The balance between Notch/Wnt signaling regulates progenitor cells’ commitment during liver repair: Mystery solved?  Mario Strazzabosco, Luca Fabris 
Philippe Metz, Antje Reuter, Silke Bender, Ralf Bartenschlager 
Platelets arrive at the scene of fibrosis……studies
Niya Aleksieva, Stuart J. Forbes  Journal of Hepatology 
Presentation transcript:

RANTES antagonism: A promising approach to treat chronic liver diseases  Silvia Affò, Ramón Bataller  Journal of Hepatology  Volume 55, Issue 4, Pages 936-938 (October 2011) DOI: 10.1016/j.jhep.2011.04.023 Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Implication of RANTES in the pathogenesis of liver fibrosis due to HCV infection. HCV entries hepatocytes and is cleaved into different proteins with biological actions (core, NS3, NS5, etc.). Some of these proteins are expressed in the membrane of hepatocytes together with MHC-I and MHC-II molecules. Moreover, infected hepatocytes secrete inflammatory cytokines. Both actions activate and recruit T-lymphocytes that secrete mediators including RANTES. Neighboring biliary cells and non-parenchymal cells (hepatic stellate cells – HSC and Kupffer cells) become activated and secrete free radicals and fibrogenic and inflammatory mediators. The inflammatory milieu activates resident HSC into myofibroblastic cells. These latter cells express CCR5 and secrete RANTES. Paracrine and autacrine actions of RANTES in HSCs stimulate intracellular signaling pathways leading to increased collagen synthesis, impaired collagen degradation and secretion of further inflammatory mediators. These actions lead to progressive fibrosis and persistent liver inflammation. The use of new RANTES receptor antagonists (e.g. Met-CCL5) could block the pathogenic effects of RANTES and attenuate the progression of liver fibrosis. Journal of Hepatology 2011 55, 936-938DOI: (10.1016/j.jhep.2011.04.023) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions